

Novartis announces FDA approval for first IL-17A antagonist Cosentyx™ (secukinumab) for moderate-to-severe plaque psoriasis patients

Jan 21, 2015

Source URL: <https://qa1.novartis.us/us-en/news/media-releases/novartis-announces-fda-approval-first-il-17a-antagonist-cosentyxtm-secukinumab-moderate-severe-plaque-psoriasis-patients-0>

List of links present in page

1. <https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-announces-fda-approval-first-il-17a-antagonist-cosentyxtm-secukinumab-moderate-severe-plaque-psoriasis-patients-0>